Lattise

latisse-header

LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information

Approved Use
LATISSE® is an FDA-approved treatment to grow eyelashes for people with inadequate or not enough lashes.


INDICATIONS AND USAGE LATISSE® (bimatoprost ophthalmic solution) 0.03%

  • is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.

 

DOSAGE AND ADMINISTRATION

  • Ensure the face is clean, makeup and contact lenses are removed.
  • Once nightly, place one drop of LATISSE® (bimatoprost ophthalmic solution) 0.03% on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes.
  • The upper lid margin in the area of lash growth should feel lightly moist without runoff.
  • Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth. Dispose of the applicator after one use.
  • Repeat for the opposite eyelid margin using a new sterile applicator. Do not reuse applicators and do not use any other brush/applicator to apply LATISSE® .
  • Do not apply to the lower eyelash.
  • Additional applications of LATISSE® will not increase the growth of eyelashes.
  • Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.

 

DOSAGE FORMS AND STRENGTHS

  • Bimatoprost ophthalmic solution 0.3 mg/mL.

 

CONTRAINDICATIONS

  • None

 

WARNINGS AND PRECAUTIONS

  • Effects on Intraocular Pressure Bimatoprost ophthalmic solution (LUMIGAN® ) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or without elevated IOP, LATISSE® lowered IOP, however, the magnitude of the reduction was not cause for clinical concern.
  • In ocular hypertension studies with LUMIGAN® , it has been shown that exposure of the eye to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect.
  • In patients using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE® may interfere with the desired reduction in IOP.
  • Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.